首页> 外文期刊>Chinese Jouranl of Integrative Medicine >Comparative Study of the Effect of Shugan Shuru Granule on Pathology and p53 Gene Expression in Patients with Hyperplastic Disease of Breast
【24h】

Comparative Study of the Effect of Shugan Shuru Granule on Pathology and p53 Gene Expression in Patients with Hyperplastic Disease of Breast

机译:疏肝舒乳冲剂对乳腺增生性疾病患者病理及p53基因表达影响的比较研究

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To study the effect of Shugan Shuru Granule (SSG) on the p53 gene expression in patients with hyperplastic disease of breast (HDB) to indirectly explore the mechanism of SSG's effect on HDB on the molecular pathological level. Methods: Sixty-six patients with HDB were allocated in the treated group and the control group, with the former treated with SSG and the latter not. All patients underwent breast operation and their diseased mammary tissues were cut out, sectioned, and observed under microscopy with HE staining and immunohistochemical staining, with ABC method adopted to estimate the degree of hyperplasia and p53 gene expression. The severity of HDB was classified into normal, mild, moderate and severe grades (marked as 0 to Ⅲ), according to the degree of hyperplasia in the mammary gland. Results: Hyperplasia in the control group mostly belonged to grade Ⅰ- Ⅲ before treatment, showing overgrowth of gland and proliferation of glandular epithelial cells, which were high columnar shaped, more stratified, with papillary or substantive dysplasia. While in the treated group, most belonged to grade 0 - Ⅰ after SSG treatment, with proliferated gland and dysplasia recovered to normal or disappeared. The positive rate of p53 gene expression in the treated group was 9.09%, and in the control group 39.39%, comparison between the two groups showing significant difference (P < 0.01), the intensity in the former was significantly weaker than that in the latter. Conclusion: SSG could not only inhibit the proliferation of mammary duct epi-thelia and lobuli, but also inhibit the over-expression of P53. Therefore, it could be regarded as an effective remedy for treatment of HDB and prevention of mammary cancer genesis.
机译:目的:研究疏肝舒乳颗粒(SSG)对乳腺增生性疾病(HDB)患者p53基因表达的影响,从分子病理学角度间接探讨SSG对HDB影响的机制。方法:将66例HDB患者分为治疗组和对照组,前者采用SSG治疗,而后者则不使用。所有患者均行乳房手术,切开患处的乳腺组织,切片,并在显微镜下进行HE染色和免疫组织化学染色观察,并采用ABC法评估其增生程度和p53基因表达。根据乳腺增生的程度,将HDB的严重程度分为正常,轻度,中度和严重等级(标记为0至Ⅲ)。结果:对照组的增生在治疗前多为Ⅰ-Ⅲ级,表现为腺体过度生长和腺上皮细胞增殖,呈高柱状,分层较多,有乳头状或实质性增生。在治疗组中,大多数在SSG治疗后属于0-Ⅰ级,腺体增生和不典型增生恢复到正常或消失。治疗组p53基因表达阳性率为9.09%,对照组为39.39%,两组比较有显着性差异(P <0.01),前者的强度明显弱于后者。 。结论:SSG不仅可以抑制乳腺上皮和小叶的增殖,而且可以抑制P53的过度表达。因此,它可以被视为治疗HDB和预防乳癌发生的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号